Screener
aTyr Pharma ATYR Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by aTyr Pharma in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: aTyr Pharma’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001339970-26-000053
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from issuance of common stock from at-the-market offerings, net of offering costs | — | 36,691 |
| Principal paid on finance lease liabilities | (287) | (264) |
| Net cash (used in) provided by financing activities | (271) | 36,525 |
| Net change in cash, cash equivalents and restricted cash | 4,677 | 6,092 |
| Cash, cash equivalents and restricted cash at beginning of period | 12,978 | 14,006 |
| Cash, cash equivalents and restricted cash at the end of period | $17,655 | $20,098 |
| Cash and cash equivalents at the end of period | $16,160 | $17,220 |
| Restricted cash at the end of period | 1,495 | 2,878 |
Item 1. Financial Statements
FAQ
- What is aTyr Pharma's net change in cash?
- aTyr Pharma (ATYR) reported net change in cash of $5.84M in Q2 2026.
- How has aTyr Pharma's net change in cash changed year-over-year?
- aTyr Pharma's net change in cash decreased by 20.0% year-over-year, from $7.3M to $5.84M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about aTyr Pharma's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude